| Schedule of Net Loss of Significant Expense |
The following table presents segment revenue and significant expenses regularly reviewed by the CODM for the years ended December 31, 2025 and 2024 (in thousands): | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | Royalty revenues | | $ | 570 | | $ | 501 | Operating expenses | | | | | | | Research and development: | | | | | | | Repibresib (VYN201) | | | 8,487 | | | 16,271 | VYN202 | | | 7,756 | | | 11,262 | Other segment items* | | | 2,994 | | | 3,413 | General and administrative | | | 11,082 | | | 13,192 | Total operating expenses | | | 30,319 | | | 44,138 | Operating loss | | | (29,749) | | | (43,637) | Other income, net | | | 3,017 | | | 3,834 | Loss from continuing operations before income taxes | | | (26,732) | | | (39,803) | Income tax expense | | | 4 | | | 4 | Loss from continuing operations | | | (26,736) | | | (39,807) | Income (loss) from discontinued operations, net of income taxes | | | 253 | | | (27) | Net loss | | $ | (26,483) | | $ | (39,834) |
* | Other segment items relate to research and development expenses that cannot be directly allocated to one specific product candidate, such as employee-related expenses, consulting, quality control, regulatory, and general IP legal expenses. |
|